Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Protagonist Therapeutics grants...
Business equity compensation

Protagonist Therapeutics grants inducement awards

Analysis based on 9 articles · First reported Aug 04, 2026 · Last updated Aug 18, 2026

Sentiment
0
Attention
0
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The inducement awards are routine equity compensation and have minimal direct market impact. They signal continued hiring and investment in talent, but the amounts are immaterial relative to the company's market capitalization.

Biotechnology Pharmaceuticals
Event Summary

AnBogen Therapeutics, Inc. (Nasdaq:PTGX) reported that on July 31, 2026, and August 17, 2026, it granted inducement awards to newly hired employees under its Amended and Restated Inducement Plan. The awards comprised options to purchase 7,300 and 5,675 shares of common stock, respectively, and restricted stock units (RSUs) to acquire 1,975 and 1,500 shares, respectively. The exercise prices were set at the closing prices on the grant dates: $136.64 on July 31 and $155.10 on August 17. The awards vest over four years and were approved by the compensation committee as material inducements to employment under Nasdaq Marketplace Rule 5635(c)(4). Protagonist is a biopharmaceutical company developing peptide therapeutics, with ICOTYDE (icotrokinra) licensed to Johnson & Johnson's Johnson & Johnson — Janssen Pharmaceuticals and rusfertide licensed to Takeda Pharmaceuticals.

Key Actions
20 AnBogen Therapeutics granted inducement awards
Entities Involved
priv
AnBogen Therapeutics
Protagonist granted inducement awards to new employees, reflecting ongoing talent acquisition. The company's pipeline includes ICOTYDE and rusfertide, with regulatory milestones ahead.
Importance 100.0 Sentiment 0.0
stock
Johnson & Johnson
Johnson & Johnson is the licensee of ICOTYDE, which is launched and in Phase 3 for additional indications. This event does not directly affect J&J.
Importance 10.0 Sentiment 0.0
subs
Johnson & Johnson — Janssen Pharmaceuticals
Johnson & Johnson — Janssen Pharmaceuticals, a J&J subsidiary, is the licensee of ICOTYDE. No direct impact from this event.
Importance 5.0 Sentiment 0.0
stock
Takeda Pharmaceutical Company
Takeda is the licensee of rusfertide, which is under FDA priority review. No direct impact from this event.
Importance 5.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA is reviewing the NDA for rusfertide. This event does not affect the FDA.
Importance 5.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Protagonist is listed and the source of the closing prices used for the awards. No direct impact.
Importance 5.0 Sentiment 0.0
Relationships
Johnson & Johnson related ↔ United States — Food and Drug Administration
Takeda Pharmaceutical Company related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.